Spots Global Cancer Trial Database for Safety and Efficacy of ThisCART19 in Patients With Refractory or Relapsed B Cell Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety and Efficacy of ThisCART19 in Patients With Refractory or Relapsed B Cell Malignancies
Official Title: A Study to Evaluate the Safety and Clinical Activity of Allogeneic Chimeric Antigen Receptor T Cells Targeting CD19 in Patients With Refractory or Relapsed B Cell Malignancies.
Study ID: NCT04384393
Conditions
Interventions
Study Description
Brief Summary: This is a study to evaluate the safety and clinical activity of ThisCART19 (Allogeneic CAR-T targeting CD19) in patients with refractory or relapsed CD19 positive B cell malignancies.
Detailed Description: This is a single-center, nonrandomized, open-label study to evaluate the safety and clinical activity of ThisCART19 in patients with refractory or relapsed CD19 positive B cell malignancies, such as acute or chronic lymphocytic leukemia, lymphoma and etc. The dose range is 0.2-60 x 10\^6 cells per kg body weight.
Keywords
Eligibility
Minimum Age: 3 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The First Affiliated Hospital of USTC (Anhui Provincial Hospital), Hefei, Anhui, China
Fundamenta Therapeutice Co.,Ltd, Suzhou, Jiangsu, China
Contact Details
Name: Xingbing Wang
Affiliation: The First Affiliated Hospital of USTC (Anhui Provincial Hospital)
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
